These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 17624828

  • 1. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.
    McIlleron H, Meintjes G, Burman WJ, Maartens G.
    J Infect Dis; 2007 Aug 15; 196 Suppl 1():S63-75. PubMed ID: 17624828
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.
    Maartens G, Decloedt E, Cohen K.
    Antivir Ther; 2009 Aug 15; 14(8):1039-43. PubMed ID: 20032533
    [Abstract] [Full Text] [Related]

  • 3. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2000 Mar 10; 49(9):185-9. PubMed ID: 11795500
    [Abstract] [Full Text] [Related]

  • 4. HIV infection-related tuberculosis: clinical manifestations and treatment.
    Sterling TR, Pham PA, Chaisson RE.
    Clin Infect Dis; 2010 May 15; 50 Suppl 3():S223-30. PubMed ID: 20397952
    [Abstract] [Full Text] [Related]

  • 5. Use of rifamycins in HIV-infected patients.
    Preboth M.
    Am Fam Physician; 2000 Sep 01; 62(5):1189-90. PubMed ID: 10997538
    [No Abstract] [Full Text] [Related]

  • 6. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
    van Oosterhout JJ, Kumwenda JJ, Beadsworth M, Mateyu G, Longwe T, Burger DM, Zijlstra EE.
    Antivir Ther; 2007 Sep 01; 12(4):515-21. PubMed ID: 17668560
    [Abstract] [Full Text] [Related]

  • 7. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients.
    Schluger NW.
    Clin Infect Dis; 1999 Jan 01; 28(1):130-5. PubMed ID: 10028083
    [Abstract] [Full Text] [Related]

  • 8. Antiretroviral therapy in AIDS patients with tuberculosis.
    Moreno S, Hernández B, Dronda F.
    AIDS Rev; 2006 Jan 01; 8(3):115-24. PubMed ID: 17078482
    [Abstract] [Full Text] [Related]

  • 9. Tuberculosis in HIV-infected patients: a comprehensive review.
    Aaron L, Saadoun D, Calatroni I, Launay O, Mémain N, Vincent V, Marchal G, Dupont B, Bouchaud O, Valeyre D, Lortholary O.
    Clin Microbiol Infect; 2004 May 01; 10(5):388-98. PubMed ID: 15113314
    [Abstract] [Full Text] [Related]

  • 10. Progressive symptoms and signs following institution of highly active antiretroviral therapy and subsequent antituberculosis therapy: immune reconstitution syndrome or infection?
    Miller RF, Shahmanesh M, Talbot MD, Wiselka MJ, Shaw PJ, Bacon C, Robertson CM.
    Sex Transm Infect; 2006 Apr 01; 82(2):111-6. PubMed ID: 16581733
    [Abstract] [Full Text] [Related]

  • 11. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 1996 Oct 25; 45(42):921-5. PubMed ID: 8927017
    [Abstract] [Full Text] [Related]

  • 12. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2002 Mar 15; 51(10):214-5. PubMed ID: 11922192
    [Abstract] [Full Text] [Related]

  • 13. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
    Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, Sungkanuparph S.
    Clin Infect Dis; 2007 Jan 01; 44(1):141-4. PubMed ID: 17143831
    [Abstract] [Full Text] [Related]

  • 14. Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries.
    Friedland G, Abdool Karim S, Abdool Karim Q, Lalloo U, Jack C, Gandhi N, El Sadr W.
    Clin Infect Dis; 2004 Jun 01; 38 Suppl 5():S421-8. PubMed ID: 15156433
    [Abstract] [Full Text] [Related]

  • 15. [Tuberculosis among HIV-infected persons in Norway].
    Ormaasen V, Maeland A.
    Tidsskr Nor Laegeforen; 2001 Nov 30; 121(29):3425-30. PubMed ID: 11826791
    [Abstract] [Full Text] [Related]

  • 16. HIV-associated tuberculosis: diagnostic and treatment challenges.
    El-Sadr WM, Tsiouris SJ.
    Semin Respir Crit Care Med; 2008 Oct 30; 29(5):525-31. PubMed ID: 18810685
    [Abstract] [Full Text] [Related]

  • 17. New TB guidelines for persons with HIV.
    AIDS Treat News; 1998 Nov 06; (No 306):6. PubMed ID: 11365963
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic and management challenges for childhood tuberculosis in the era of HIV.
    Marais BJ, Graham SM, Cotton MF, Beyers N.
    J Infect Dis; 2007 Aug 15; 196 Suppl 1():S76-85. PubMed ID: 17624829
    [Abstract] [Full Text] [Related]

  • 19. [Tuberculosis and HIV coinfection in three patients: the possibilities for simultaneous treatment].
    van Oosterhout JJ, Boeree MJ, Burger DM, de Lange WC, van Crevel R, Koopmans PP.
    Ned Tijdschr Geneeskd; 2003 Mar 01; 147(9):369-72. PubMed ID: 12661452
    [Abstract] [Full Text] [Related]

  • 20. Ritonavir/saquinavir safety concerns curtail antiretroviral therapy options for tuberculosis-HIV-co-infected patients in resource-constrained settings.
    Gray A, Abdool Karim SS, Gengiah TN.
    AIDS; 2006 Jan 09; 20(2):302-3. PubMed ID: 16511431
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.